Loading...

Lexaria Bioscience Corp.

LEXXWNASDAQ
Healthcare
Biotechnology
$0.15
$-0.07(-30.42%)

Lexaria Bioscience Corp. (LEXXW) Company Profile & Overview

Explore Lexaria Bioscience Corp.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Lexaria Bioscience Corp. (LEXXW) Company Profile & Overview

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

SectorHealthcare
IndustryBiotechnology
CEOMr. Richard C. Christopher

Contact Information

250 765 6424
740 McCurdy Road, Kelowna, NV, V1X 2P7

Company Facts

7 Employees
CountryUS
Actively Trading

Frequently Asked Questions

;